Filing Flows › Charles River Laboratories International (CRL) › Capital expenditures
Charles River Laboratories International (CRL) capital expenditures by quarter
Charles River Laboratories International's capital expenditures were $46.8M in Q3 2026 (third quarter 2026), +50% from Q2 2026. Over the last 7 quarters it ranged from $31.1M (Q2 2026) to $89.0M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $46.8M | +50% | +32% |
| Q2 2026 | $31.1M | -44% | -12% |
| Q1 2026 | $55.9M | -37% | -6% |
| Q4 2025 | $89.0M | +150% | — |
| Q3 2025 | $35.6M | +0.8% | — |
| Q2 2025 | $35.3M | -40% | — |
| Q1 2025 | $59.3M | — | — |
Q3 2026 at a glance
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart follows the revenue to costs, profit and cash.
Questions
What is Charles River Laboratories International's capital expenditures?
Charles River Laboratories International's capital expenditures were $46.8M in Q3 2026 (third quarter 2026), +50% from Q2 2026.
How has Charles River Laboratories International's capital expenditures changed?
Over the last 7 quarters it ranged from $31.1M (Q2 2026) to $89.0M (Q4 2025).
Q3 2026 results → · How Charles River Laboratories International makes money →